OSSIANIX

Ossianix is an antibody engineering company that utilizes single-domain antibodies (VNARs) from the shark to develop novel biopharmaceuticals for a number of therapeutic areas including CNS, immunology and oncology. The company was founded by former senior executives from Wyeth and Pfizer and is based in Philadelphia, PA, with research laboratories in Stevenage, UK... The company is headquartered in the University City Science Center in downtown Philadelphia and has research laboratories at the Stevenage Bioscience Catalyst in Stevenage, Herts, UK. Ossianix was founded by Frank S Walsh, Corey Goodman and Lynn Rutkowski who have had distinguished careers in academia, Pharma and Biotech and bring a wealth of experience to the problem of delivering the next generation of Biologics products. The company started operations in 2012 with funding from Lundbeck Pharmaceuticals, BioAdvance and the ALS Association. Current programs focus on autoimmunity, neurodegereration, ALS,pain and..

Also known as: Ossianix, Inc.

Registration numbers: FC032376 (CH)

Primary location: Stevenage United Kingdom